Literature DB >> 8834321

Endocervical glandular atypia: a "new" problem for the cytologist.

D C Wilbur1.   

Abstract

New patterns of cellular presentation on cervical smears have become more frequent since the introduction of new sampling devices which provide increased material from the upper portions of the endocervical canal. The normal histologic variability of the endocervical canal, as well as the presence of tubal metaplasia, infectious and inflammatory reactions, squamous lesions involving endocervical glands, and true endocervical neoplastic lesions in these areas, have presented the cytologist with a variety of cellular appearances which may cause difficulties in differential diagnosis. Recognition of these entities, their cytologic manifestations, and the effects of increased high endocervical sampling, will allow the cytologist to begin the process of gaining the experience necessary to assess these new cellular patterns. A potential management protocol for patient follow-up is presented which will allow the user to investigate such cases in an efficient and cost effective manner.

Entities:  

Mesh:

Year:  1995        PMID: 8834321     DOI: 10.1002/dc.2840130515

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  2 in total

1.  A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study.

Authors:  Randy L Carter; Le Kang; Kathleen M Darcy; James Kauderer; Shu-Yuan Liao; William H Rodgers; Joan L Walker; Heather A Lankes; S Terence Dunn; Eric J Stanbridge
Journal:  Cancer Causes Control       Date:  2012-10-17       Impact factor: 2.506

2.  A fast Monte Carlo EM algorithm for estimation in latent class model analysis with an application to assess diagnostic accuracy for cervical neoplasia in women with AGC.

Authors:  Le Kang; Randy Carter; Kathleen Darcy; James Kauderer; Shu-Yuan Liao
Journal:  J Appl Stat       Date:  2013       Impact factor: 1.404

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.